Literature DB >> 9705584

Incidence of primary central nervous system cancers in South and East Netherlands in 1989-1994.

G A van der Sanden1, L J Schouten, J A van Dijck, J P van Andel, J Coebergh.   

Abstract

About 2,000 patients with primary CNS cancers, as defined by the ICD-O, were registered in four adjacent cancer registries in South and East Netherlands in 1989-1994, covering a population of more than 5 million people. About 85% of the patients were registered through pathological laboratories, concentrated in four centers for neurosurgery. Patients with a clinical-radiological diagnosis only (about 50% in the age-group of 75 years and older) were mainly identified through medical records of hospitalized patients. World-standardized incidence rates of 6.5 and 4.4 per 100,000 person-years for males and females, respectively, were similar to those reported in other European cancer registries. Eighty-five percent of histologically verified primary CNS cancers were of glial origin, 6% were lymphomas and 4% embryonal tumors. Gliomas were mainly of astrocytic (about 85%) and oligodendroglial or mixed type (about 10%). Without additional review most astrocytic tumors could be classified into high-grade (70-75%) and low-grade astrocytomas (20-25%). Different grading systems were used for gliomas, but the dichotomy of astrocytomas according to differentiation grade seemed to correspond well with the definition of the WHO. Age-specific incidence rates for low-grade astrocytomas were remarkably constant. The incidence of high-grade astrocytomas increased sharply with age and declined after the age of 70, whereas the incidence of clinically diagnosed tumors continued to increase. Male/females-ratios were relatively high for these tumor types (1. 6-1.7). We conclude that the registration of primary CNS cancers in the Netherlands may be almost complete and valid for gliomas, embryonal tumors and lymphomas.

Entities:  

Mesh:

Year:  1998        PMID: 9705584     DOI: 10.1159/000026177

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  5 in total

Review 1.  Boron neutron capture therapy for glioblastoma multiforme.

Authors:  Catharina M van Rij; Abraham J Wilhelm; Wolfgang A G Sauerwein; Arie C van Loenen
Journal:  Pharm World Sci       Date:  2005-04

2.  Health-related quality of life of significant others of patients with malignant CNS versus non-CNS tumors: a comparative study.

Authors:  Florien W Boele; Jan J Heimans; Neil K Aaronson; Martin J B Taphoorn; Tjeerd J Postma; Jaap C Reijneveld; Martin Klein
Journal:  J Neurooncol       Date:  2013-07-04       Impact factor: 4.130

3.  Space-time clustering of glioma cannot be attributed to specific histological subgroups.

Authors:  M P W A Houben; J W W Coebergh; J M Birch; C C Tijssen; C M van Duijn; R J Q McNally
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

4.  The association between antihypertensive drugs and glioma.

Authors:  M P W A Houben; J W W Coebergh; R M C Herings; M K Casparie; C C Tijssen; C M van Duijn; B H Ch Stricker
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

5.  Evaluation of an online tool about the expected course of disease for glioblastoma patients-A qualitative study.

Authors:  Eva van Diest; Wendy H Oldenmenger; Marit Eland; Walter Taal
Journal:  Neurooncol Pract       Date:  2022-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.